Skip to content
Skip to navigation menu
19 January 2008
Cardiff University research could improve breast cancer treatment for women who become resistant to drugs such as tamoxifen.
While drugs such as tamoxifen have been successful in treating breast cancer, for a significant proportion of sufferers the drugs either fail to work, or after an initial successful response, the patient relapses as the cancer acquires or possesses resistance to the drug.
However researchers from the Welsh School of Pharmacy’s Tenovus Centre for Cancer Research have discovered that inhibiting the activity of a certain protein in the cancer could prevent or even reverse the resistance to tamoxifen. The researchers noticed that when breast cancer cells grown in the laboratory develop resistance to tamoxifen, they show a large increase in the activity of a protein known as Src – and by stopping this activity resistance to tamoxifen can be prevented and even reversed.
Dr Stephen Hiscox of the Welsh School of Pharmacy, who led the research team and has just been appointed as a Research Council UK Academic Fellow, explained: "We have previously shown that when breast cancer cells become resistant to medicines such as tamoxifen in the laboratory, they become more aggressive with an invasive behaviour. These are characteristics that can be promoted by Src, a protein which we have recently shown to be more active in tamoxifen-resistant than tamoxifen-sensitive breast cancer cells."
The collaborative research between Tenovus and AstraZeneca also found that the aggressive, invasive behaviour in the cells could be reduced by treating them with a specific inhibitor of Src activity, AZD0530, which also made the tamoxifen-resistant cells sensitive to tamoxifen again. In addition, the research found that co-treating the cells with a combination of tamoxifen and AZD0530 could actually prevent drug resistance occurring in the first place.
The Src inhibitor AZD0530 developed by AstraZeneca is currently in early clinical trials. If the results seen in the laboratory can be reproduced in the clinic, this approach could offer a substantial clinical benefit to a large number of women with breast cancer, as Professor Robert Nicholson, Director of the Tenovus Centre for Cancer Research, explains: "Whilst little is known about the mechanisms used by breast cancers to become resistant to common therapies such as tamoxifen, it remains a significant clinical problem. Therefore the ability to restore sensitivity to therapy, or to even prevent resistance arising in the first place, could be of huge benefit to a large number of breast cancer patients."
Medical and medical related research and education across the University’s School of Medicine, the School of Biosciences, Welsh School of Pharmacy and other academic schools is making a major contribution to tackling breast cancer.
Developing new anti-cancer medicines
New vaccine hope for leading viral cause of birth defects
'War Horse' author tops Cardiff Children’s Literature Festival
This is an externally hosted beta service offered by Google.